Navigation Links
PLC Systems to Present at OneMedForum in San Francisco
Date:1/6/2012

MILFORD, Mass., Jan. 6, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF) today announced that it will participate in the OneMedForum 2012 investor conference at the Sir Francis Drake Hotel in San Francisco, California. PLC is scheduled to present on Wednesday, January 11, 2012 at 11:30 am local time in the Windsor Room. Presenting for the company will be Mark R. Tauscher, President and CEO.

The presentation will be streamed live and accessible at the time by visiting the OneMedForum website (www.onemedplace.com, following links for the OneMedForum 2012). Within 24 hours after the presentation, a webcast replay will be available at PLC's website (www.plcmed.com) by accessing the link on the investor relations page. The webcast will be archived on the company's website for 30 days following completion of the event.

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2010, a copy of which is on file with the SEC.

Contact: Mary T. Conway
508-520-2545
mconway@plcmed.com


'/>"/>
SOURCE PLC Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
9. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
10. PLC Systems Reports Fourth Quarter 2007 Results
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):